New drug tested for tough cancers
Disease control
Terminated
This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC